Home > Journals > Medicine > European Journal of Dermatology > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
European Journal of Dermatology
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn’s disease


European Journal of Dermatology. Volume 13, Number 3, 258-60, May 2003, Therapy

Free Article  

Author(s) : Alessandro ZACCAGNA, Alberto BERTONE, Paolo PUIATTI, Franco PICCIOTTO, Tatiana SPRUJEVNIK, Renato SANTUCCI, Francesco Paolo ROSSINI

Summary : Here we report a case of Pyoderma gangrenosum (PG) associated with Crohn’s disease successfully treated with infliximab. The efficacy of this drug in many inflammatory diseases has already been reported, but its use in PG has only been seen in very few cases. Our study confirms that this therapy is a valid alternative solution for treating PG, which is often unresponsive to conventional therapies.

Keywords : Crohn’s disease, infliximab, neutrophilic dermatoses, Pyoderma gangrenosum, therapy, tumor-necrosis-factor-alpha

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]